Beta microglobulin

Beta-2 Microglobulin (β2M): A Comprehensive Reference

Important Preliminary Note: Beta-2 microglobulin (β2M) is not a dietary supplement, botanical extract, or exogenous natural ingredient in the conventional sense. It is an endogenous human protein — a constitutively produced component of every nucleated cell in the body. It does not exist as a commercial supplement, nor does it appear in any recognized pharmacopoeia, dietary supplement monograph (e.g., NIH Office of Dietary Supplements, German Commission E, ESCOP, WHO Monographs), or regulatory framework as an ingredient to be consumed. The following article therefore documents what authoritative scientific and medical literature establishes about β2M as a biological molecule, biomarker, and subject of clinical research, with strict adherence to source-verifiable facts only. Any framing of β2M as a "natural ingredient" capable of being supplemented lacks scientific support in peer-reviewed or regulatory literature.

1. Identity and Chemical Characterization

1.1 Names and Gene

β2 microglobulin (B2M) is a component of MHC class I molecules. In humans, the β2 microglobulin protein is encoded by the B2M gene. The human beta-2-microglobulin (β2M) gene, B2M, is a small gene located on chromosome 15 (15q21.1), consisting of 4 exons that encode a full-length nonglycosylated protein (12 kDa) composed of 119 amino acids.

Common names and abbreviations used in the scientific literature include: beta-2-microglobulin, β2-microglobulin, β2M, B2M, β2m, and B2-M. Its molecular synonym in UniProt databases is B2MG_HUMAN (accession P61769).

1.2 Protein Structure

It is a single polypeptide chain with a molecular mass of 11.6 kDa that shows homology to immunoglobulins and HLA, suggesting a common evolutionary origin. The mature protein is predicted to contain 99 amino acids. It is a 100-amino acid protein of relatively small molecular weight (11,800 Da, size 11 Å), encoded by a gene in chromosome 15 in humans. The secondary structure of the molecule consists of two large beta sheets that are linked together by a single disulfide bond. The tertiary structure of the molecule is thus similar to the constant domain of the immunoglobulins.

The protein has a predominantly beta-pleated sheet structure that can form amyloid fibrils in some pathological conditions. The subunit formed by the β2m protein is distinguished from the heavy chains in that the sequence is practically invariable and in that its polypeptide chain is not glycosylated.

1.3 Biological Occurrence

β2-microglobulin, a protein with a molecular weight of 11.8 kDa, is ubiquitously expressed in all nucleated cells and present in most of the biological fluids, including serum, urine, and synovial fluid, in vertebrates. In its soluble form, β2m is present in various biological fluids, and is also stored within neutrophil granules and platelets. Additionally, it can be secreted into the extracellular environment by activated immune and epithelial cells.

The encoded antimicrobial protein displays antibacterial activity in amniotic fluid.

2. Discovery and Historical Context

2.1 Initial Discovery

Beta-2 microglobulin was first discovered in 1964 in the urine of subjects with Wilson's disease or cadmium poisoning. It is a 100-amino acid protein of relatively small molecular weight (11,800 Da, size 11 Å) and it is encoded by a gene in chromosome 15 in humans. The formal published characterization is attributed to Berggård and Bearn (1968): Beta-2-microglobulin had been found in the serum of normal individuals and in the urine in elevated amounts in patients with Wilson disease, cadmium poisoning, and other conditions leading to renal tubular dysfunction (Berggård and Bearn, 1968).

β2M was discovered in urine samples from patients with chronic kidney dysfunction due to cadmium poisoning (Berggård and Bearn, 1968) and was subsequently isolated from the sera of healthy individuals and milk from cows. The β2M protein was characterized and found to be associated with the α-chain of MHC-I (Grey et al., 1973; Nakamuro et al., 1973).

Cunningham et al. (1973) reported the complete amino acid sequence of the beta-2-microglobulin protein.

2.2 Traditional and Historical Use

There is no documented traditional or historical use of beta-2 microglobulin as a medicinal preparation, botanical remedy, dietary supplement, or intentionally consumed substance in any culture or time period. β2M does not appear in any pharmacopeial monograph, traditional medicine system (e.g., Traditional Chinese Medicine, Ayurveda, European herbal medicine), or historical therapeutic compendium as an ingredient, preparation, or remedy. Its entire documented history is as an endogenous protein first identified in the context of toxicological and clinical pathological investigation in the twentieth century.

3. Physiological Roles and Mechanisms of Action

3.1 Role in MHC Class I Antigen Presentation

Beta-2-microglobulin (β2m) constitutes the invariant light chain of the tri-molecular major histocompatibility complex class I (MHC I), where it non-covalently associates with the transmembrane heavy chain responsible for presenting peptide antigens to CD8+ T cells.

β2 microglobulin associates not only with the alpha chain of MHC class I molecules, but also with class I-like molecules such as CD1 (5 genes in humans), MR1, the neonatal Fc receptor (FcRn), and Qa-1 (a form of alloantigen). Mice models deficient for the β2 microglobulin gene have been engineered. These mice demonstrate that β2 microglobulin is necessary for cell surface expression of MHC class I and stability of the peptide-binding groove.

beta 2-Microglobulin (beta 2m) binds non-covalently to the alpha 1, alpha 2 and alpha 3 domains of the alpha-chain of Class I major-histocompatibility-complex (MHC) molecules.

3.2 Iron Homeostasis and the Neonatal Fc Receptor

The neonatal Fc receptor (FcRn) is a heterodimer of a nonclassical MHC class I alpha chain and B2M that binds the two most abundant serum proteins, IgG and albumin, after their constitutive cellular uptake. FcRn binds both proteins, thus acting as a salvage pathway, protecting them from lysosomal degradation and extending the catabolic half-lives of both proteins.

An additional function is association with the HFE protein, together regulating the expression of hepcidin in the liver which targets the iron transporter ferroportin on the basolateral membrane of enterocytes.

3.3 Renal Filtration and Catabolism

In healthy individuals, β2m dissociates from the major histocompatibility complex-I (MHC-I), is released into the plasma, and is carried to the kidneys for degradation. It is freely filtered by the kidney glomeruli, and almost all of it is reabsorbed and metabolised in the proximal tubule.

Urinary beta2 microglobulin levels are high in renal tubular disorders despite normal plasma levels, reflecting a dysfunction in reabsorption by the proximal tubules. Glomerular disease is characterized by elevated serum B2M and low urine B2M, while tubular disease is characterized by low serum B2M and elevated urine B2M.

3.4 Immune System Activation Marker

Serum and plasma beta2 microglobulin values have emerged as markers for activation of the cellular immune system, as well as a tumor marker in certain hematological malignancies.

3.5 Amyloidogenic Properties

A modified variant of β2m, later characterized as desLys58-β2m (dK58β2m), was first found in the serum of patients with systemic lupus erythematosus and rheumatoid arthritis. Subsequent studies revealed that dK58β2m is generated via a two-step proteolytic process: native β2m is first cleaved at the C-terminal side of lysine 58 by the complement component C1s, followed by removal of lysine 58 by a carboxypeptidase B-like activity. This cleavage induces a conformational change in β2m, conferring amyloidogenic properties that increase its propensity to aggregate and form fibrils.

3.6 Neurological Effects

Researchers have identified β2-microglobulin (B2M), a component of major histocompatibility complex class 1 (MHC I) molecules, as a circulating factor that negatively regulates cognitive and regenerative function in the adult hippocampus in an age-dependent manner. B2M is elevated in the blood of aging humans and mice, and it is increased within the hippocampus of aged mice and young heterochronic parabionts.

4. Normal Reference Ranges

About one half of the endogenous serum levels — normal mean levels of up to 1.2 mg/L with a range of 0–2.4 mg/L — are contributed to by the turnover of lymphocytes. The normal range for beta-2 microglobulin levels varies slightly between laboratories but is generally around 0.7 to 1.8 mg/L. Levels within this range typically indicate no significant issues related to this biomarker.

The plasma β2-microglobulin concentration is increased in dialyzed patients, with a level ranging from 30 to 50 mg/L, much higher than the normal value of 0.8 to 3.0 mg/L.

5. Scientific Evidence by Area of Clinical Use

Beta-2 microglobulin has no clinical evidence as an exogenously administered supplement. All documented human clinical evidence pertains to measurements of endogenous β2M as a biomarker in the context of disease diagnosis, staging, prognosis, and monitoring. The following sections review this evidence by disease area.

5.1 Hematological Malignancies — Multiple Myeloma

The increased levels of serum beta-2 microglobulin in patients with multiple myeloma have been associated with a poor prognosis. Pretreatment levels of serum beta-2 microglobulin were estimated in 70 previously untreated patients with multiple myeloma. In a multivariate analysis, serum beta-2 microglobulin levels and stage were the most significant prognostic factors for survival independent of other risk factors associated with a worse prognosis.

There was a clear difference in survival duration observed between the patients with a high pretreatment level of beta-2 microglobulin and stage III (none alive at 5 years) compared with patients with normal levels and stage I (80% alive at five years) (p less than .001).

In myeloma, β2M is increased in proportion to the number of myeloma cells and therefore is regarded as the best single indicator of tumour burden in myeloma.

The International Staging System (ISS) for multiple myeloma, published by the International Myeloma Working Group in 2005, relies centrally on β2M. ISS staging is based on: Stage I: β2-microglobulin less than 3.5 mg/L and serum albumin greater than or equal to 35 g/L; Stage III: β2-microglobulin greater than or equal to 5.5 mg/L; Stage II: Neither stage I nor stage III.

Following an International Myeloma Working Group (IMWG) review of almost 12,000 patients, it was determined that β2M less than 3.5 mg/L is associated with a favourable prognosis (provided albumin level is normal). In 2015, the ISS was updated to include chromosomal abnormalities and lactate dehydrogenase levels. This enables better stratification of newly diagnosed patients with respect to their prognosis and forms the most commonly used staging system for myeloma today: the Revised International Staging System (R-ISS).

To establish these new groups, the International Myeloma Working Group used data from 4,445 patients with newly diagnosed multiple myeloma taken from 11 international trials.

A prospective study of 160 patients confirmed that Sβ2M is an excellent marker of response to treatment, as an overall agreement between Sβ2M and clinical outcome was observed in 95% of patients. In myeloma patients with normal renal function, beta-2-microglobulin is a major feature related to survival and could be used for treatment stratification.

In MM, Sβ2M was highly correlated with the total body burden of myeloma cells as derived from the staging of Durie and Salmon, both at diagnosis and in remission (residual tumor mass) (p less than 0.001).

Evidence strength: Strong. β2M is a validated, guideline-incorporated prognostic biomarker for multiple myeloma, supported by prospective clinical studies and multinational trials involving thousands of patients. Its use in the ISS and R-ISS represents a high level of clinical evidence.

5.2 Hematological Malignancies — Lymphoma and CLL

In lymphoma, β2-microglobulin levels usually correlate with disease stage and tumor burden in patients with CLL (chronic lymphocytic leukemia), with increasing levels associated with a poorer prognosis. Significantly elevated beta-2 microglobulin levels can be found in lymphoproliferative disorders such as monoclonal gammopathies of immunoglobulin G (multiple myeloma), malignant lymphomas, and chronic lymphocytic leukemia despite preserved renal function.

In diffuse large B-cell lymphoma, the high β2M group exhibited distinct adverse clinical features, such as older age, male sex, poor performance status, elevated lactate dehydrogenase, impaired renal function, advanced stage disease, multiple extranodal involvement, presence of B-symptoms, non-germinal center B-cell-like subtype, bone marrow involvement, bulky disease, and higher IPI, R-IPI, and NCCN-IPI risk groups.

Evidence strength: Moderate to strong for prognostic use. β2M is incorporated into standard clinical prognostic indices for lymphoma (e.g., FLIPI-2 for follicular lymphoma). Confounding by renal function must be considered when interpreting values.

5.3 Kidney Disease and Renal Function

There is currently an unmet need for better biomarkers across the spectrum of renal diseases. β2M has been revisited as a biomarker in patients with chronic kidney disease and end-stage renal disease. Prior to reviewing the numerous clinical studies in the area, the basic biology of β2M was described, focusing in particular on its role in maintaining the serum albumin levels and reclaiming the albumin in tubular fluid through the actions of the neonatal Fc receptor.

It is a novel glomerular filtration marker that has stronger association with adverse outcomes than creatinine.

Urinary excretion of β2M either in the form of fractional excretion of β2M (FE-β2M) or 24-h urine β2M excretion has been used in the diagnosis of tubulo-interstitial diseases. This study examined children with glomerular (N = 114), tubular (N = 50), or other (N = 18) renal diseases and showed that children with tubulo-interstitial disease had significantly higher FE-β2M (mean 4.27%) compared to children with glomerular disease alone.

The relationship of plasma B2M levels to clinical and cardiovascular outcomes was studied in 142 patients (mean age of 67 years) at different stages of CKD. B2M levels increased with CKD stage and thus were highest in hemodialysis patients. Higher B2M levels were independently associated with overall and cardiovascular mortality and cardiovascular events in the whole cohort and with cardiovascular events in the predialysis cohort.

Evidence strength: Moderate. β2M is a useful marker for distinguishing glomerular from tubular pathology and for predicting outcomes in CKD, but it is not yet in routine clinical guideline use for CKD staging the way creatinine and GFR are. Large database studies support its prognostic utility.

5.4 Dialysis-Related Amyloidosis

Almost half a century has elapsed since the first description of dialysis-related amyloidosis (DRA), a disorder caused by excessive accumulation of β-2 microglobulin (B2M).

Beta-2–microglobulin (beta-2m) amyloidosis is a disabling condition that affects patients undergoing long-term hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). Beta-2m is a major constituent of amyloid fibrils. Through accumulation, it invades synovial membranes and osteoarticular sites. As a result, it causes destructive osteoarthropathies, such as carpal tunnel syndrome, flexor tenosynovitis, subchondral bone cysts, and erosions, as well as pathologic fractures.

When hemodialysis or peritoneal dialysis are required due to kidney failure, β2m is not efficiently removed from the plasma, leading to increased concentrations by up to 60-fold. Remarkably, despite being transported throughout the body, β2m accumulates into amyloid plaques specifically in skeletal tissues of dialysis patients.

Many risk factors are associated including (1) prolonged duration of dialysis, (2) advanced age, (3) dialysate of low purity, and (4) the use of a dialysis membrane with poor biocompatibility.

A 12-center study was designed to assess factors affecting the development and progression of β2-microglobulin amyloidosis in long-term dialysis. A total of 221 patients who were on hemodialysis for more than five years were evaluated. The data demonstrate that patients treated solely by AN69 membranes display signs of bone amyloidosis less frequently than do those treated by Cell membranes.

Improvements in dialysis have led to a decrease in the incidence of DRA. In many countries, DRA is considered a "disappearing act" or complication.

Evidence strength: Strong. The causal role of β2M accumulation in DRA is well-established across decades of observational and mechanistic studies. Multicenter clinical data confirm membrane type as a modifiable risk factor.

5.5 Cadmium Toxicity and Renal Tubular Monitoring

Beta-2 microglobulin was initially discovered in the urine of subjects with cadmium toxicity and is still used to detect renal toxicity caused by drugs or heavy metals. Renal excretion can increase by 100–1000 times normal with cadmium exposure.

Kidney disease associated with chronic cadmium exposure is primarily due to proximal tubule cell damage. This results in a sustained decline in glomerular filtration rate (GFR) and tubular proteinuria, evident from an increased excretion of the low-molecular weight protein β2-microglobulin (β2M). Thus, an increase in β2M excretion is often used to reflect the impact of cadmium on tubular protein reabsorption.

Urinary beta-2 microglobulin (β2m) estimation has been added to pre-employment and periodic medical surveillance programmes for cadmium workers.

Evidence strength: Strong for occupational/environmental monitoring. Urinary β2M is an established marker in cadmium nephrotoxicity surveillance, supported by epidemiological and occupational health studies.

5.6 HIV Infection and AIDS-Related Dementia

Normal mean levels of β2M are up to 1.2 mg/L with a range of 0–2.4 mg/L. Mean β2M levels were found to be 1.28 mg/L in controls (normal range 0–2.4 mg/L), 2.69 mg/L in asymptomatic HIV-infected subjects, 12.14 mg/L in those with persistent generalized lymphadenopathy, and 39.29 mg/L in patients with acquired immunodeficiency syndrome.

Plasma B2M levels are higher in AIDS dementia complex (ADC) patients compared to non-ADC patients and serves as a risk factor for ADC progression; however, it cannot independently predict neurological outcomes following HIV infection. In contrast, B2M in the CSF was increased in ADC patients and has been proved to be a valuable indicator of ADC severity.

Evidence strength: Moderate. CSF β2M is a useful surrogate marker in HIV-associated CNS disease. Serum β2M reflects immune activation but is less specific for neurological outcomes in HIV.

5.7 Glioma and Brain Tumors

Patients with malignant gliomas exhibited elevated preoperative serum B2M levels. Glioma patients with high serum B2M levels experienced shorter survival times. Multivariate Cox analysis determined the relationship between B2M levels (hazard ratio = 1.92, 95% confidence interval: 1.05–3.50, P = 0.034) and the overall survival of glioma patients.

High preoperative serum B2M levels correlated with malignant glioma and a poor prognosis. Serum B2M shows promise as a novel biomarker for predicting patient prognosis and reflecting the therapeutic response.

Evidence strength: Preliminary. The glioma data are from a single-center preliminary clinical study; independent validation is required.

5.8 Inflammatory Bowel Disease

The diagnostic utility of beta-2 microglobulin (B2-M) levels was investigated in 78 IBD patients and 30 healthy controls. B2-M serum levels were examined in 43 ulcerative colitis (UC) patients, 35 with Crohn's disease (CD), and 30 control subjects using an enzymatic method. The mean serum B2-M levels in the control group, UC, and CD were 1.71, 2.41, and 2.24 respectively.

Evidence strength: Preliminary. This single study with a modest sample showed elevated B2M in IBD, but β2M is not in clinical use as a standard IBD biomarker; further validation is required.

5.9 Aging and Neurogenesis (Preclinical and Early Human Data)

Circulating β2-microglobulin, a component of MHC I, increases with age, promoting age-related cognitive decline and decreased neurogenesis.

B2M has been reported to tick up in the blood of HIV patients with dementia, in people who become cognitively impaired while undergoing chronic dialysis, and perhaps even in the cerebrospinal fluid (CSF) of patients with Alzheimer's or Parkinson's disease.

In the brain, B2M and MHC I can act independent of their canonical immune function to regulate normal brain development, synaptic plasticity and behavior. Increased systemic levels of soluble B2M have been implicated in cognitive impairments associated with chronic hemodialysis. Moreover, increased soluble B2M has also been detected in the cerebrospinal fluid (CSF) of patients with HIV-dementia and Alzheimer's disease.

Co-first authors at UCSF and Stanford confirmed the age-related increase of plasma B2M. Two-year-old mice had about four times the amount of three-month-olds. Similarly, the researchers found more B2M in archived CSF from healthy older people aged 60 to 95 compared to those 20 to 45.

Evidence strength: Preclinical (animal) and correlational (human). The causal hypothesis that elevated circulating B2M drives cognitive aging is based substantially on mouse experiments and epidemiological correlations. Direct human interventional evidence is absent.

5.10 Cardiovascular Risk in Kidney Disease

Elevated serum B2M is associated with increased cardiovascular risk, arterial calcification, malnutrition, inflammation, and atherosclerosis in those with kidney disease. Baseline B2M levels were associated with vascular calcification but not with arterial stiffness or bone density.

In the Framingham Heart Study (n = 7,065), an increased level of plasma β2M was linked to increased risks of prevalent and incident hypertension.

Evidence strength: Moderate. Association data from large epidemiological studies (including the Framingham Heart Study) support β2M as a cardiovascular risk marker, particularly in CKD populations. Causality and direction of effect require further investigation.

5.11 Diabetes and Diabetic Nephropathy

The beta-2-microglobulin (B2M) level of the serum and urine was determined in 61 diabetics and 15 control patients by enzyme-immunoassay. In patients with daily protein excretion exceeding 300 mg there was a significant positive correlation between serum creatinine, daily protein excretion, and B2M level of the serum and urine. In patients with less than 300 mg and in those with more than 300 mg daily protein excretion, the B2M levels of the serum and urine were significantly higher than in the controls. Determination of the B2M level is a sensitive method in the diagnosis of diabetic nephropathy. Simultaneous measurement of B2M level in the serum and urine detects nephropathy at an early stage and thus it may be of value in the prevention of the disease.

Evidence strength: Preliminary to moderate. Small human studies support urinary and serum B2M as early markers of diabetic kidney disease; not yet a standard clinical test for this indication.

6. Body Systems and Health Areas Associated with β2M

• Immune System: Core structural component of MHC class I; regulates antigen presentation to CD8+ T cells; modulates innate immune cell (neutrophil) function.
• Renal System: Freely filtered and catabolized by the kidney; elevated serum and urine levels mark both glomerular and tubular dysfunction.
• Hematological/Oncological System: Established prognostic and staging marker in multiple myeloma, lymphoma, and CLL.
• Musculoskeletal System: Pathological accumulation causes DRA with joint destruction, bone cysts, carpal tunnel syndrome, and pathologic fractures in dialysis patients.
• Central Nervous System: Elevated CSF and plasma levels correlate with HIV-associated dementia; preclinical evidence of a pro-aging effect on hippocampal neurogenesis.
• Cardiovascular System: Elevated plasma levels associated with cardiovascular events, vascular calcification, and hypertension, particularly in CKD populations.
• Iron Metabolism: Participates in HFE-mediated regulation of hepcidin; B2M deficiency leads to iron excess and hemochromatosis-like phenotype.

7. Measurement Forms and Reported Clinical Levels

β2M is measured in three principal biological matrices in clinical practice:

• Serum/Plasma β2M: The normal range for beta-2 microglobulin levels varies slightly between laboratories but is generally around 0.7 to 1.8 mg/L.
• Urine β2M: Urinary excretion of β2M either in the form of fractional excretion of β2M (FE-β2M) or 24-h urine β2M excretion has been used in the diagnosis of tubulo-interstitial diseases. In pre-employment studies of workers not occupationally exposed to cadmium, the overall geometric mean urinary β2m was 76 micrograms/L (adjusted to specific gravity 1016).
• Cerebrospinal Fluid (CSF) β2M: Used as a marker for HIV-associated dementia and has been investigated in Alzheimer's disease.

Specific serum cut-offs reported in studies include:

• Multiple myeloma ISS staging: Stage I uses β2M less than 3.5 mg/L (with serum albumin ≥35 g/L); Stage III uses β2M ≥5.5 mg/L.
• In HIV disease: asymptomatic HIV-infected subjects showed mean β2M of 2.69 mg/L; those with persistent generalized lymphadenopathy 12.14 mg/L; AIDS patients 39.29 mg/L.
• In hemodialysis patients, plasma β2M concentration ranges from 30 to 50 mg/L, compared to the normal value of 0.8 to 3.0 mg/L.

There are no dosage forms for exogenous supplementation, as β2M is not an ingredient used in dietary supplements. No published human clinical trials have administered β2M orally or parenterally to healthy or patient populations for therapeutic or supplementation purposes.

8. Safety Considerations

Because β2M is not a supplement or drug ingredient, there are no established safety profiles for exogenous administration. The safety considerations documented in the scientific literature relate exclusively to consequences of pathologically elevated endogenous levels:

8.1 Dialysis-Related Amyloidosis

Beta-2m amyloidosis is a disabling condition that affects patients undergoing long-term hemodialysis (HD) or continuous ambulatory peritoneal dialysis (CAPD). Case reports involving patients with near–end-stage renal disease also exist. Hemodialysis-related amyloidosis (HRA) is a form of systemic amyloidosis with a predilection for the synovium and bone that occurs with a disturbingly high frequency among patients on long-term hemodialysis. The clinical features include carpal tunnel syndrome, erosive arthropathy, spondyloarthropathy, lytic bone lesions, and pathologic fractures.

Monocytes, the precursors of macrophages, cannot degrade β2m fibrils, and both monomeric β2m and fibrillar β2m are cytotoxic to these cells. β2m fibrils also impair the formation of bone-resorbing osteoclasts from monocytes and reduce the viability of osteoblasts, the cell type that produces bone.

8.2 Genetic Deficiency and Immune Consequences

Diseases associated with B2M include Amyloidosis, Hereditary Systemic 6 and Immunodeficiency 43. A mutation in this gene has been shown to result in hypercatabolic hypoproteinemia. Loss of this function causes iron excess and hemochromatosis. Defects in B2M are the cause of hypercatabolic hypoproteinemia (HYCATHYP).

8.3 Pro-Aging and Neurological Risk

β2-microglobulin (β2m) is an important pro-aging factor that interferes with neurogenesis and worsens cognitive functions. The preclinical evidence for this mechanism was generated primarily in mouse models; its precise relevance to human aging is still under active investigation.

8.4 Confounding of Clinical Interpretation

β2-microglobulin levels also rise with worsening renal dysfunction, leading some investigators to suggest a measure of β2-microglobulin adjusted for the glomerular filtration rate (GFR). This GFR-adjusted β2-microglobulin requires validation in prospective confirmatory studies.

High levels of β2M can also be a sign of kidney damage and therefore can be raised in someone with pre-existing kidney problems such as chronic kidney disease (CKD). This complicates interpretation of β2M as a tumor marker in patients with concurrent renal impairment.

9. Absence of Supplement or Dietary Use

A systematic search of authoritative sources — including the NIH Office of Dietary Supplements, WHO Monographs, ESCOP monographs, German Commission E, the European Pharmacopoeia, the United States Pharmacopeia (USP), EFSA dietary supplement assessments, and NCCIH — reveals no listing, monograph, or regulatory assessment of beta-2 microglobulin as a dietary supplement, botanical ingredient, nutraceutical, or health food component. No peer-reviewed clinical trial has tested oral or parenteral β2M supplementation in human subjects. No established preparations, doses, formulations, or indications for supplemental use exist in the peer-reviewed literature.

β2M should therefore not be conflated with other "beta" compounds marketed as supplements (such as beta-glucan, beta-carotene, or beta-alanine), which are entirely distinct chemical entities with separate pharmacological profiles and independent regulatory classifications.

References

• Wikipedia — Beta-2 microglobulin
• ScienceDirect Topics — Beta-2 Microglobulin overview
• Argyropoulos et al. (2017). Rediscovering Beta-2 Microglobulin As a Biomarker across the Spectrum of Kidney Diseases. Frontiers in Medicine.
• OMIM Entry *109700 — BETA-2-MICROGLOBULIN; B2M
• GeneCards — B2M Gene
• Frontiers in Oncology — The immune-related role of beta-2-microglobulin in melanoma (2022)
• Dasgupta & Ying (2022). Beta-2 Microglobulin Amyloidosis: Past, Present, and Future. PMC.
• Medscape — Dialysis-Related Beta-2m Amyloidosis: Background, Etiology, Epidemiology
• Medscape — Beta2 Microglobulin: Reference Range, Interpretation, Collection and Panels
• PubMed — Prognostic importance of beta-2-microglobulin in multiple myeloma (1992)
• PubMed — Bataille et al. Beta-2-microglobulin in myeloma: optimal use for staging, prognosis, and treatment (1984)
• Blood — Beta-2-Microglobulin in Myeloma: Optimal Use for Staging, Prognosis, and Treatment—A Prospective Study of 160 Patients
• PMC — Prognostic significance of β2-microglobulin decline index in multiple myeloma
• PMC — Evaluation of the Revised International Staging System in an independent cohort of unselected patients with multiple myeloma
• Myeloma UK — The International Staging System (ISS) and the Revised (R)-ISS
• Oncotarget — Prognostic significance of serum beta-2 microglobulin in lymphoma
• PubMed — Serum beta 2-microglobulin as a biomarker in inflammatory bowel disease (2014)
• PubMed — Clinical significance of beta-2-microglobulin in diabetes mellitus (1989)
• PMC — Serum beta2-microglobulin acts as a biomarker for severity and prognosis in glioma patients (2024)
• PMC — β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis (2015)
• Nature Medicine — β2-microglobulin is a systemic pro-aging factor (Smith et al., 2015)
• PMC — The Role of Beta2-Microglobulin in Central Nervous System Disease (2024)
• PMC — Beta-2-Microglobulin Levels in Human-Immunodeficiency Virus Infected Subjects
• PMC — Characterization of the Response of Primary Cells Relevant to Dialysis-Related Amyloidosis to β2-Microglobulin Monomer and Fibrils
• PMC — Extracellular matrix components modulate different stages in β2-microglobulin amyloid formation
• PMC — Molecular comparisons of the beta 2-microglobulin-binding site in class I MHC alpha-chains
• PMC — β2-microglobulin gene duplication in cetartiodactyla
• PMC — Glomerular hyperfiltration and β-2 microglobulin as biomarkers of incipient renal dysfunction in cancer survivors
• PMC — Urinary beta 2 microglobulin in the biological monitoring of cadmium workers
• PMC — Evidence Linking Cadmium Exposure and β2-Microglobulin to Increased Risk of Hypertension in Diabetes Type 2 (2023)
• PMC — Urinary β2-Microglobulin Predicts the Risk of Hypertension in Populations Chronically Exposed to Environmental Cadmium (2025)
• PMC — Cadmium Complexed with β2-Microglobulin, Albumin and Lipocalin-2 rather than Metallothionein Cause Megalin:Cubilin Dependent Toxicity (2019)
• ScienceDirect — Cloning and sequence analysis of the β2-microglobulin
• PMC — HIV-1-Associated Neurocognitive Disorders: Is HLA-C Binding Stability to β2-Microglobulin a Missing Piece of the Pathogenetic Puzzle? (2018)
• bioRxiv — Beta-2-microglobulin stimulates neutrophil phagocytosis of bacteria and apoptotic cells (2025)